Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New digital program aims to ease migraine pain without drugs

NCT ID NCT07642414

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This study is testing a digital care program for adults with migraine. The program includes a wearable device that uses nerve stimulation, personalized exercises, and support from a care team. The goal is to see if it can reduce the number of migraine days per month. About 140 people will take part in this pilot study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older * Documented or clinical history of episodic or chronic migraine (with or without aura) for at least 12 months, consistent with ICHD-3 criteria. Verification of diagnosis must be established using one or more of the following methods: participant-provided medical records, documented pharmacy prescription history, or validated diagnostic screening instruments. * Passes ID-Migraine Screener with a score of 2 or more "yes" answers to the following question: During the last 3 months, did you experience any of the following with your migraines? (1) Your migraines limited your ability to complete your daily activities for more than one day; (2) You felt nauseated or sick to your stomach; (3) Light bothered you (a lot more than when you don't have migraines). * Migraine onset occurred at age 50 years or younger * Minimum of 4 migraine days during the 28-day baseline run-in period, as confirmed by the study eDiary * At least 80% eDiary compliance (minimum of 22 out of 28 days) during the prospective baseline run-in period * Currently on a stable dose of traditional oral migraine preventive medication (e.g., topiramate, beta-blockers, amitriptyline) for at least 90 days prior to the start of the 28-day baseline period, or taking no preventive medication * Currently on a stable dose of CGRP monoclonal antibodies (e.g., Aimovig, Emgality, Ajovy, Vyepti) or OnabotulinumtoxinA (Botox) for at least 180 days (6 months) prior to the start of the 28-day baseline period * Willingness to maintain current preventive and as-needed (acute) medication regimens (e.g., triptans, NSAIDs, or abortive gepants) and refrain from initiating any brand new pharmacological or clinical treatments (e.g., nerve blocks, Botox, or infusions) for the duration of the 12-week intervention period * Sufficient physical mobility to engage with the exercise therapy component of the program, with or without reasonable accommodations; participants reporting significant mobility restrictions (e.g., wheelchair use) will be eligible pending a clinical safety review by a Study Physician or Physical Therapist * Active commercial health insurance coverage (either as the primary policyholder or a covered dependent) through an employer-sponsored health plan, commercial health insurer, or an affiliated benefit partner eligible for digital health solution deployment * US resident * Has a valid email account * Personal ownership of a smartphone (iOS 15 or later, or Android 10 or later) with Bluetooth capability, app store access, and compatibility with the eDiary * Able to understand and provide voluntary informed consent Exclusion Criteria: * Presence of a cardiac pacemaker, implanted or wearable defibrillator, spinal cord stimulator, pain pump, insulin pump, or any other active implanted electronic medical device * Presence of a metal implant in the head or neck (excluding dental work) * Supraorbital nerve blocks or infusion treatments for migraine received within 4 months before the start of the baseline period * Presence of other primary or secondary headache disorders (e.g., cluster headache, New Daily Persistent Headache, or post-traumatic headache); Note: Medication Overuse Headache (MOH) is NOT an exclusion criterion * History of major head or neck injuries or any physical condition (e.g., severe cervical spine instability) that, in the opinion of the Principal Investigator and/or Study Physician, would make the exercise therapy component of the program unsafe; History of major cardiovascular events (e.g., stroke, arrhythmia, myocardial infarction) * History of major migraine complications (e.g., migrainous infarction or aura-triggered seizure) * Presence of fever, chills, or night sweats lasting five or more days and not improving * Significant change in headache pattern, including headaches that are becoming much more severe or frequent, represent a new type of pain, wake the participant from sleep, or worsen with positional changes (e.g., coughing, bearing down, or changing position) * Recent changes in vision, mental status, sensation, or strength; or new onset of jaw pain or neck stiffness * Unexplained significant weight loss (past 3 months), or persistent weakness/numbness in the extremities (past 3 months) * Known history of conditions that may compromise the immune system * Head trauma within the past 2 weeks or diagnosis of a spinal fracture or shoulder dislocation within the past 3 months * Any major trauma, fracture, or significant injury (e.g., car accident, sports injury) within the past 3 months * Any major surgery within the past 3 months * Inability to stand up from a chair without assistance (unless the participant utilizes a wheelchair and has been cleared via PT review) * History of falling due to balance, weakness, vision, or other physical limitations within the past 3 months * Current diagnosis of epilepsy or active malignancy (history of cancer within the last 5 years) * Presence of a cognitive or neurological disorder (e.g., dementia, Parkinson's disease) that may interfere with study participation * Currently unmanaged psychiatric disorder (e.g., schizophrenia, substance abuse, or severe major depressive disorder/anxiety) that, in the opinion of the investigator, could prevent compliance with study instructions * Pregnant, planning to become pregnant during the study, or currently breastfeeding * Currently institutionalized * Insufficient proficiency with the English language to take part in study procedures or complete online surveys * Current or previous enrollment in any Hinge Health Program or participation in prior Hinge Health research studies * Current ownership or previous use of an Enso device or other prescribed high-frequency electrical stimulation therapy for the treatment of pain * Participation in an investigational study within 30 days prior to screening * Planned travel outside of the U.S. within the first month of enrollment * Current employees or contractors of Hinge Health, Inc. or L\&E Research, and their immediate family members

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hinge Health, Inc.

    San Francisco, California, 94105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.